Journal of cancer research & therapy最新文献_第2页

HTLV-1 can be involved in acceleration of different nonhematological cancers HTLV-1可参与加速不同的非血液学癌症

Journal of cancer research & therapy Pub Date : 2019-02-05 DOI: 10.14312/2052-4994.2019-1

Kouznetsova Vl, S. Chen, Tsigelny If

引用次数: 4

The acceleration of metastases after tumor removal and the paradoxical phenomenon of concomitant tumor resistance 肿瘤切除后转移的加速和伴随肿瘤耐药的矛盾现象

Journal of cancer research & therapy Pub Date : 2018-11-03 DOI: 10.14312/2052-4994.2018-7

Montagna Dr, P. Chiarella, R. Meiss, Ruggiero Ra

引用次数: 3

Ecological model links proto-oncogene to high incidence of metastatic cancers in African-Americans 生态模型将原癌基因与非裔美国人转移性癌症的高发联系起来

Journal of cancer research & therapy Pub Date : 2018-09-03 DOI: 10.14312/2052-4994.2018-6

H. C.

引用次数: 1

Characterizing tobacco use in an American cancer center’s catchment area can help direct future research priorities 描述美国癌症中心集水区的烟草使用情况有助于指导未来的研究重点

Journal of cancer research & therapy Pub Date : 2018-09-03 DOI: 10.14312/2052-4994.2018-5

Schnoll R, K. S., M. A., G. K

引用次数: 1

Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases 结直肠癌:衰老、髓源性抑制细胞和治疗:两例报告

Journal of cancer research & therapy Pub Date : 2018-08-03 DOI: 10.14312/2052-4994.2018-4

Bueno V, Mandaliti Al, Forones Nm

{"title":"Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases","authors":"Bueno V, Mandaliti Al, Forones Nm","doi":"10.14312/2052-4994.2018-4","DOIUrl":"https://doi.org/10.14312/2052-4994.2018-4","url":null,"abstract":"Background: Colorectal cancer (CRC) is the third cause of cancer in the world and age is a risk factor for this disease. Treatments such as surgical resection and adjuvant chemotherapy have increased the mean survival and the recurrence-free survival. However, the decrease in the frequency and function of effector T cells in addition to the increase in the frequency of myeloid-derived suppressor cells that have been reported in older individuals could contribute to the impaired efficacy in immunity against cancer. We aimed to evaluate if in old patients with CRC, the pre-treatment immunological status was correlated with patients’ outcome. Methods: Patients with CRC (n = 2) were submitted to curative surgical resection or curative surgical resection plus capecitabine/oxaliplatine. Blood was collected for the evaluation of immunological status prior to the treatment and correlated with patients’ outcome. Results: Approximately 20 months after surgery the patients presented with recurrence-free survival. Patient 2 (66-years-old) with CRC and peritoneal metastases presented higher frequency and absolute cell number of myeloid-derived suppressor cells than patient 1 (58-years-old) with CRC. Patient 2 presented a low frequency of effector memory CD8 T cells in addition to high accumulation of effector memory reexpressing CD45RA (CD4 and CD8 T cells). Conclusion: Immunological status was correlated with the disease complexity and our results suggest that removing/reducing myeloid-derived suppressor cells helps in the control of cancer progression. Immunological status is a useful, low invasive tool to identify the disease complexity and the results can be used in the future development of personal treatment according to the immunological status of the patient.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87969329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical study of the treatment of multiple brain metastases from adenocarcinoma of the lung by simultaneous integrated boost intensity-modulated radiotherapy 同步综合增强调强放疗治疗肺腺癌多发脑转移的临床研究

Journal of cancer research & therapy Pub Date : 2018-05-02 DOI: 10.14312/2052-4994.2018-3

Q. Shao, S. Liu, W. Wang, Y. Zhang, F. Li, J. Li

引用次数: 0

Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters 吉西他滨联合吲哚-3-甲醇或二甲双胍对胰腺癌细胞系药物疗效的影响:人平衡核苷转运体的作用

Journal of cancer research & therapy Pub Date : 2018-02-05 DOI: 10.14312/2052-4994.2018-2

S. Joseph, B. Word, B. Lyn-Cook

{"title":"Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters","authors":"S. Joseph, B. Word, B. Lyn-Cook","doi":"10.14312/2052-4994.2018-2","DOIUrl":"https://doi.org/10.14312/2052-4994.2018-2","url":null,"abstract":"Pancreatic cancer is one of the most lethal carcinomas in the United States. In accord with the American Cancer Society pancreatic cancer is anticipated to move from the third to the second leading cause of deaths in the United States by 2020. Although the standard treatment for advanced pancreatic cancer is gemcitabine (GEM), the response rate is less than 20%. Chemoresistance is a hallmark of this cancer, and modulation of drug transporters expression has been shown to increase cancer drug efficacy. Studies have shown that human equilibrative nucleoside transporters (hENTs) expression patterns may predict GEM treatment efficacy. This study investigated whether or not GEM in combination with metformin (MET) or indole-3-carbinol (I3C) increases cytotoxicity and modulates hENT1 and hENT4. Pancreatic cancer cells from males and females were treated for 24 or 72h with GEM and/or MET or I3C. Cell viability, drug interactions, and protein and mRNA expression levels of hENTs were assessed. Treatment with GEM and/or MET or I3C showed cell line specific reductions in pancreatic cancer cell proliferation, and modulation of hENT1 and hENT4 expression. Response to GEM and MET/I3C may be dependent upon the genetic profile of the tumor and the level of expression of a specific transporter. The sensitivity of GEM could depend on the method of treatment, whether cells were pre-treated with MET or I3C, which studies, including our own, have showed that pre-treatment with I3C increased upregulation of hENT1 expression in pancreatic cancer cell lines.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"60 1","pages":"6-17"},"PeriodicalIF":0.0,"publicationDate":"2018-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83752136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Prognostic serum biomarkers for colorectal cancer – Review 结直肠癌预后血清生物标志物研究综述

Journal of cancer research & therapy Pub Date : 2018-01-01 DOI: 10.14312/2052-4994.2018-1

Y. Yovchev, E. Enchev, E. Dimitrov, G. Minkov, S. Nikolov

引用次数: 0

New salvage vincristine, carmustine, cyclophosphamide, and prednisone (VBCP) chemotherapy for relapsed/refractory multiple myeloma in the modern era: A case series 新抢救长春新碱、卡莫司汀、环磷酰胺和强的松(VBCP)化疗治疗复发/难治性多发性骨髓瘤:一个病例系列

Journal of cancer research & therapy Pub Date : 2017-11-02 DOI: 10.14312/2052-4994.2017-12

A. Khan, J. Muzaffar, L. Mramba, J. Moreb

{"title":"New salvage vincristine, carmustine, cyclophosphamide, and prednisone (VBCP) chemotherapy for relapsed/refractory multiple myeloma in the modern era: A case series","authors":"A. Khan, J. Muzaffar, L. Mramba, J. Moreb","doi":"10.14312/2052-4994.2017-12","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-12","url":null,"abstract":"We report our experience with vincristine, carmustine (BCNU), cyclophosphamide, and prednisone (VBCP), a regimen given in the outpatient setting to patients with multiple myeloma (MM) resistant to almost all the available novel/targeted therapies. Ten patients received salvage VBCP who were heavily pretreated with a median of 5.5 prior treatment regimens including lenalidomide, pomalidomide, bortezomib, carfilzomib, cyclophosphamide, and autologous stem cell transplantation. The objective response rate (≥PR) was 60%, with an additional 30% achieving stable disease (SD). The median time to progression for patients with ≥SD was 3.6 months. The median progression free survival was 4.4 months while the median overall survival was 12.8 months. Despite severe myelosuppression being the main toxicity, 61% of the subsequent cycles were given on time. Treatment-related mortality was not observed. Our results suggest VBCP is a highly active and tolerable salvage regimen among heavily pretreated MM patients who already failed many of the novel agents.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"18 1","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2017-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80778918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An anaplastic cardiac large cell lymphoma: A case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin’s lymphoma from the Czech Lymphoma Study Group (CLSG) database 间变性心脏大细胞淋巴瘤:捷克淋巴瘤研究组(CLSG)数据库中新诊断的非霍奇金淋巴瘤累及心脏的病例报告和分析

Journal of cancer research & therapy Pub Date : 2017-11-02 DOI: 10.14312/2052-4994.2017-13

C. Lobello, A. Janíková, L. Křen, M. Hermanová, A. Šprláková‐Puková, J. Krejci, Š. Pospíšilová, R. Pytlík, M. Hamouzová, D. Belada, V. Procházka, J. Ďuraš, H. Mociková, M. Trněný

{"title":"An anaplastic cardiac large cell lymphoma: A case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin’s lymphoma from the Czech Lymphoma Study Group (CLSG) database","authors":"C. Lobello, A. Janíková, L. Křen, M. Hermanová, A. Šprláková‐Puková, J. Krejci, Š. Pospíšilová, R. Pytlík, M. Hamouzová, D. Belada, V. Procházka, J. Ďuraš, H. Mociková, M. Trněný","doi":"10.14312/2052-4994.2017-13","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-13","url":null,"abstract":"We report a rare case of anaplastic large cell ALK+ lymphoma (ALCL) with initial asymptomatic cardiac involvement. A 59-year-old male with infiltration of the right ventricular wall underwent standard combined chemotherapy (CHOP) and achieved remission without significant cardiac impairment. Additionally, we report the actual incidence of cardiac lymphoma in newly diagnosed non-Hodgkin Lymphomas (NHLs). In total, 16 patients with cardiac lymphoma were found (0.1% NHLs) in the Czech Lymphoma Study Group database. DLBCL was the most frequent histology subtype (50%), and ALCL was identified in 12.5% of cases. At initial diagnosis, the median age was 55.5 (range 21-74) years and 59% were men. None of the 16 patients with cardiac involvement had isolated heart lymphoma. The response to first-line therapy was 79% in 14/16 evaluable patients. The median progression-free survival and overall survival were nearly the same -approximately 3.5 years (range; 0.05-16.7ys), while the median follow up was 4 years.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"28 1","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2017-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79106582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1